ABBVIE INC. overview

Allergan Aesthetics launches new AA Signature Program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans PR Newswire NORTH CHICAGO, Ill., Jan. 29, 2025 AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes NORTH CHICAGO, Ill. , Jan. 29, 2025 /PRNewswire/ -- In response to growing demand for personalized, patient-centric aesthetic solutions 1,2 , Allergan Aesthetics, an AbbVie Company, is proud to unveil the new AA Signature...

AbbVie Completes Acquisition of Nimble Therapeutics PR Newswire NORTH CHICAGO, Ill., Jan. 23, 2025 Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities NORTH CHICAGO, Ill. , Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now...

AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology PR Newswire NORTH CHICAGO, Ill. and SAN DIEGO, Jan. 23, 2025 Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is eligible to receive future option fees and milestones of up to $1.64B NORTH CHICAGO, Ill. and SAN DIEGO , Jan. 23, 2025 /PRNewswire/ -- AbbVie...

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma PR Newswire SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 SHANGHAI and NORTH CHICAGO, Ill. , Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical...

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma PR Newswire SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 SHANGHAI and NORTH CHICAGO, Ill. , Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical...

AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma PR Newswire NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 NORTH CHICAGO, Ill. and SHANGHAI , Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical trials...

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program PR Newswire NORTH CHICAGO, Ill. and ROCKVILLE, Md., Jan. 13, 2025 Pivotal data evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet age-related macular degeneration (wet AMD) are expected in 2026 AbbVie and REGENXBIO will plan the Phase 3 clinical program of investigational ABBV-RGX-314 in diabetic retinopathy (DR) NORTH CHICAGO, Ill. and ROCKVILLE, Md. , Jan. 13, 2025...

AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire NORTH CHICAGO, Ill., Jan. 9, 2025 NORTH CHICAGO, Ill. , Jan. 9, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 . Management will participate in a fireside chat at 10:15 a.m. Central time . A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An...